Oppenheimer & Co. Inc. cut its stake in shares of VolitionRX Ltd (NYSEAMERICAN:VNRX) by 67.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 12,760 shares of the medical research company’s stock after selling 26,887 shares during the period. Oppenheimer & Co. Inc.’s holdings in VolitionRX were worth $72,000 as of its most recent SEC filing.
Separately, Ladenburg Thalmann Financial Services Inc. raised its stake in VolitionRX by 44.4% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 32,500 shares of the medical research company’s stock valued at $102,000 after buying an additional 10,000 shares during the last quarter.
Shares of VNRX stock opened at $5.36 on Thursday. VolitionRX Ltd has a 1 year low of $1.67 and a 1 year high of $6.84.
In related news, Director Martin Charles Faulkes acquired 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was acquired at an average price of $3.75 per share, with a total value of $37,500.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Corp Ltd Eight acquired 50,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were bought at an average cost of $5.95 per share, with a total value of $297,500.00.
VolitionRX Company Profile
VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.
Further Reading: How Investors Use a Balance Sheet
Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.